Augmentation of interleukin-2 immunotherapeutic effects by lymphokine-activated killer cells and allogeneic stimulation in murine tumor cells

Keyphrases

• 2-cycles 11%
• 4-cycle 11%
• Additional Dose 11%
• Adoptive Transfer 11%
• Allogeneic 22%
• Allogeneic Response 11%
• Allogeneic Stimulation 100%
• Alloimmune Response 11%
• Antitumor Effect 11%
• Antitumor Efficacy 11%
• C57BL 11%
• Cell Stimulation 100%
• Cell Suspension 11%
• Consecutive Days 11%
• Cytotoxicity 11%
• Fundamental Needs 11%
• Further Development 11%
• Immunotherapeutics 100%
• Implant Survival 11%
• Improved Survival 11%
• Interleukin-2 100%
• Intraperitoneal Tumor 22%
• Lung 11%
• Lymphokine-activated Killer Cells 100%
• Lymphokine-activated Killers 33%
• Microenvironment 11%
• Murine Tumors 100%
• Potentiation Effect 11%
• Pulmonary Tumor 11%
• Splenocytes 11%
• Successful Therapy 11%
• Syngeneic 22%
• Tumor 11%
• Tumor Cells 100%
• Tumor Challenge 11%
• Tumor Model 11%
• Tumor Site 11%
• Tumor Tissue 22%

Immunology and Microbiology

• C57BL 6 Mouse 11%
• Cell Suspension 11%
• Cytotoxicity 11%
• Immunotherapy 22%
• Interleukin 2 100%
• Lymphokine 33%
• Lymphokine Activated Killer Cell 100%
• Mouse 22%
• Precursor 11%
• Splenocyte 11%
• Syngenic 22%
• Tumor Cell 100%